PBM Kickback Prohibition Act
Bill Summary
Prohibits pharmacy benefit managers (middlemen who manage prescription drug benefits) from taking kickbacks, or secret payments, from drug manufacturers. Requires them to act in the best interest of patients and plan sponsors.
Sponsored By
Bill Journey
- Mar 12, 2026
- May 21, 2026You Are Here
The committee will review the bill, debate amendments, and vote on whether to advance it to the full chamber.
- TBD
The full chamber debates the bill, may amend it, and votes on whether to pass it.
- TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
- TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.
Why It Matters
This bill affects people with prescription drug coverage, particularly those with high medication costs, by potentially lowering their out-of-pocket expenses. It also impacts pharmacy benefit managers and drug manufacturers by changing the way they negotiate and receive payments.
Impact Areas
Support & Opposition
- Republican1
Documents
1
Full text opens on congress.gov, the official source.
Bill Details
- Health
Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.